Trial · NCT03148899
Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep
NCT03148899, Phase 2, Completed, George Washington University; results first posted 2023-01-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep. Trials, record NCT03148899. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03148899
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep
- NCT number
- NCT03148899
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 32 participants, actual
- Lead sponsor
- George Washington University
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- Oxytocin Intranasal Spray, Placebo Intranasal Spray
- First posted
- 2017-05-11
- Last updated
- 2023-01-31
- Results first posted
- 2023-01-31
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of Obstructive Events | Assessed on Visit 1- Day 1, Visit 2- Day 29 | |
| Secondary | Respiratory Rate | Assessed on Visit 1- Day 1, Visit 2- Day 29 | |
| Secondary | Incidence Proportion of Bradycardia | Assessed on Visit 1- Day 1, Visit 2- Day 29 | Event-associated bradycardias were identified as a heart rate reduction of 5 bpm or more from the average heart rate during the 5 s preceding an event to the lowest heart rate either during an event or within 5 s immediately after an event. Incidence proportion, or risk, of bradycardia was calculated as follows: the number of events that resulted in bradycardia divided by the total number of events. This analysis was done using custom MATLAB (MathWorks) code to study heart rate and peripheral capillary oxyhemoglobin saturation (SPO2) before and after apnea and hypopnea events. |
| Secondary | O2 Minimum | Assessed on Visit 1- Day 1, Visit 2- Day 29 |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Duration of Obstructive Events | Assessed on Visit 1- Day 1, Visit 2- Day 29 | seconds | MEAN | |
| SECONDARY | Respiratory Rate | Assessed on Visit 1- Day 1, Visit 2- Day 29 | breaths per minute | MEAN | |
| SECONDARY | Incidence Proportion of Bradycardia | Assessed on Visit 1- Day 1, Visit 2- Day 29 | proportion of events | MEAN | |
| SECONDARY | O2 Minimum | Assessed on Visit 1- Day 1, Visit 2- Day 29 | % of Oxygen Saturation | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Obstructive Events | Oxytocin | 22.72 | Standard Deviation 4.59 | seconds | |
| Duration of Obstructive Events | Placebo | 24.66 | Standard Deviation 5.12 | seconds | |
| Respiratory Rate | Oxytocin | 17.39 | Standard Deviation 3.50 | breaths per minute | |
| Respiratory Rate | Placebo | 16.69 | Standard Deviation 3.24 | breaths per minute | |
| Incidence Proportion of Bradycardia | Oxytocin | 0.08 | Standard Deviation 0.07 | proportion of events | |
| Incidence Proportion of Bradycardia | Placebo | 0.14 | Standard Deviation 0.07 | proportion of events | |
| O2 Minimum | Oxytocin | 94.31 | Standard Deviation 1.80 | % of Oxygen Saturation | |
| O2 Minimum | Placebo | 92.44 | Standard Deviation 4.24 | % of Oxygen Saturation |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Experimental: Oxytocin, Then Placebo | 16 | |
| Overall Study | STARTED | Experimental: Placebo, Then Oxytocin | 16 | |
| Overall Study | COMPLETED | Experimental: Oxytocin, Then Placebo | 16 | |
| Overall Study | COMPLETED | Experimental: Placebo, Then Oxytocin | 16 | |
| Overall Study | NOT COMPLETED | Experimental: Oxytocin, Then Placebo | 0 | |
| Overall Study | NOT COMPLETED | Experimental: Placebo, Then Oxytocin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Oxytocin | 0 | 32 |
| Total, all-cause mortality | Placebo | 0 | 32 |
| Total, other adverse events | Oxytocin | 0 | 32 |
| Total, other adverse events | Placebo | 0 | 32 |
| Total, serious adverse events | Oxytocin | 0 | 32 |
| Total, serious adverse events | Placebo | 0 | 32 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32862007 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Oxytocin vs Placebo: deaths from any cause | Trial comparisons |
| Oxytocin vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03148899
GET https://conductscience.org/api/trials/v1/NCT03148899/registered